Suppr超能文献

丙型肝炎病毒携带者肝内淋巴细胞脱颗粒与 IFNL4 多态性和 ALT 水平相关。

Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels.

机构信息

INSERM, U823, Grenoble, France Université Joseph Fourier-Grenoble 1, Faculté de Médecine.

INSERM, U823, Grenoble, France Université Joseph Fourier-Grenoble 1, Faculté de Médecine Pole DiGi-Dune, Centre Hospitalier Universitaire de Grenoble, La Tronche, France.

出版信息

J Infect Dis. 2014 Jun 15;209(12):1907-15. doi: 10.1093/infdis/jiu016. Epub 2014 Jan 9.

Abstract

BACKGROUND

The polymorphisms of IFNL4 are strongly associated with both spontaneous hepatitis C virus (HCV) clearance and response to peg-IFN-α/ribavirin treatment. To further establish the biological effects of the IFNL4 and rs1297860 variations, we studied the activity of liver immune cells.

METHODS

Fresh liver samples were collected from HCV-infected patients before any treatment and from NASH patients as controls. Degranulation activity of each lymphocyte type was assessed by the surface expression of CD107a. IFNL4 polymorphisms and HCV genotypes were determined.

RESULTS

In the liver, frequency of CD107a(+) immune cells was significantly higher in HCV patients compared to NASH patients. Higher degranulation activity was observed in lymphocytes of HCV patients with favorable IFNL4 genotypes compared to patients with unfavorable genotypes. Multivariate regression analyses indicated that serum ALT levels were dependent on both Metavir activity score and frequency of CD107a positive NKT cells. The high level of degranulation activity observed before treatment was associated with a high HCV RNA decline at the early stage of peg-IFN-α/ribavirin treatment in patients with favorable genotypes.

CONCLUSIONS

These data underline that intrahepatic lymphocyte degranulation activity in HCV-infected patients is associated with IFNL4 polymorphisms and contributes to the clearance of HCV in patients with favorable genotypes under antiviral therapy.

摘要

背景

IFNL4 的多态性与自发性丙型肝炎病毒 (HCV) 清除和对聚乙二醇干扰素-α/利巴韦林治疗的反应密切相关。为了进一步确定 IFNL4 和 rs1297860 变异的生物学效应,我们研究了肝免疫细胞的活性。

方法

从 HCV 感染患者在任何治疗前和 NASH 患者(对照组)采集新鲜肝组织样本。通过 CD107a 的表面表达评估每种淋巴细胞类型的脱颗粒活性。确定 IFNL4 多态性和 HCV 基因型。

结果

在肝脏中,与 NASH 患者相比,HCV 患者的 CD107a(+)免疫细胞频率明显更高。与不利基因型的患者相比,具有有利 IFNL4 基因型的 HCV 患者的淋巴细胞脱颗粒活性更高。多变量回归分析表明,血清 ALT 水平既依赖于 Metavir 活动评分,也依赖于 CD107a 阳性 NKT 细胞的频率。在具有有利基因型的患者中,治疗前观察到的高水平脱颗粒活性与聚乙二醇干扰素-α/利巴韦林治疗早期 HCV RNA 下降有关。

结论

这些数据表明,HCV 感染患者肝内淋巴细胞脱颗粒活性与 IFNL4 多态性相关,并有助于抗病毒治疗中具有有利基因型的患者清除 HCV。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验